Viridian (VRDN) Climbs 33% on Looming Drug Commercialization

Viridian Therapeutics Inc. (NASDAQ:VRDN) is one of the 10 Stocks Turning Heads With Double-Digit Gains.

Viridian Therapeutics extended gains for a second day on Tuesday, soaring 33.36 percent to close at $18.75 apiece, as investor sentiment was bolstered by the looming commercialization of its eye disease treatment.

In an updated report, Viridian Therapeutics Inc. (NASDAQ:VRDN) announced readiness for the launch of veligrotug, its treatment for active and chronic thyroid eye disease (TED).

For illustration purposes only. Photo by Marta Branco on Pexels

It said that it already hired a field team, including sales, to support the commercialization and supply chain infrastructure, and engaged with physicians, payers, and key opinion leaders for the treatment.

“We believe we are well-prepared and well-positioned to deliver a successful launch. With the positive topline data from REVEAL-1 and REVEAL-2, in active and chronic TED, respectively, we believe that subcutaneous elegrobart has the potential to be the simplest and most convenient treatment for TED,” Viridian Therapeutics Inc. (NASDAQ:VRDN) President and CEO Steve Mahoney said.

The company also submitted a marketing authorization application with the European Medicines Agency last January, which was accepted for review in February 2026.

Veligrotug aside, Viridian Therapeutics Inc. (NASDAQ:VRDN) widened its net loss attributable to common shareholders by 30 percent in the first quarter of the year to $92 million from $70.69 million in the same period last year.

Total revenues soared by 96 percent to $141 million from $72 million year-on-year.

While we acknowledge the risk and potential of VRDN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than VRDN and that has 10,000% upside potential, check out our report about the cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.